Eiger BioPharmaceuticals Inc EIGR

NAS: EIGR | ISIN: US28249U1051   27/09/2024
8,500 USD (0,00%)
(0,00%)   27/09/2024

18 januari 2024 · Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan · Persbericht

4 januari 2024 · Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split · Persbericht

9 november 2023 · Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

12 september 2023 · Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta · Persbericht

5 september 2023 · Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

14 augustus 2023 · Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update · Persbericht

29 juni 2023 · Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO · Persbericht

28 juni 2023 · Eiger BioPharmaceuticals to Host Business Update Call Tomorrow · Persbericht

11 mei 2023 · Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

3 mei 2023 · Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) · Persbericht

13 april 2023 · Eiger BioPharmaceuticals Strengthens Management Team with New Appointments · Persbericht

16 maart 2023 · Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update · Persbericht

8 februari 2023 · New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 · Persbericht

29 december 2022 · EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

8 december 2022 · Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint · Persbericht

7 december 2022 · Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 · Persbericht

2 december 2022 · EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

11 november 2022 · Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate · Persbericht

8 november 2022 · Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences · Persbericht

3 november 2022 · Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update · Persbericht

Mijn selecties